Recent Updates
Recently added Catalysts
ALT Negative Sentiment Score: 20/100

Altimmune, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Key Takeaway: The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in Altimmune, Inc. The suit claims that Altimmune misrepresented the potential of its drug pemvidutide, overstating its efficacy and commercial prospects based on results from the MOMENTUM Trial. The lawsuit suggests that investors were misinformed about Altimmune's business operations, which could result in significant losses for shareholders. Affected investors are encouraged to contact the law firm for a potential recovery of their losses.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against Altimmune, indicating potential legal troubles for the company.
  • Investors are urged to consider their losses, highlighting dissatisfaction with the company's performance.
  • The lawsuit alleges that the company misled investors regarding the prospects of its drug, pemvidutide.

Full Press Release Details

Investors can contact the law firm at no cost to learn more about recovering their losses
LOS ANGELES, June 24, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Altimmune, Inc. ("Altimmune" or the "Company") (NASDAQ: ALT) investors that a class action has been filed on behalf of investors. Altimmune investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or click here to join the case via www.portnoylaw.com. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) Altimmune overstated the potential for pemvidutide to stand out from competing GLP-1 agonists based on the drug's efficacy and tolerability results observed in the MOMENTUM Trial; (2) accordingly, the MOMENTUM Trial results were less significant to pemvidutide's clinical, commercial, and competitive prospects than Defendants had led investors to believe; (3) as a result of all the foregoing, Defendants had overstated Altimmune's prospects for finding a strategic partner to develop pemvidutide; and (4) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Please visit our website to review more information and submit your transaction information.
The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.
Lesley F. Portnoy, Esq.
Admitted CA and NY Bar
Attorney Advertising

Tags

Securities Litigation

Frequently Asked Questions

How can Altimmune investors contact the law firm?

Investors can reach attorney Lesley Portnoy at 310-692-8883 or via email at lesley@portnoylaw.com.

What is the purpose of the class action against Altimmune?

The class action aims to address alleged misstatements by Altimmune regarding pemvidutide's efficacy and market prospects.

Is there a cost for investors to learn about their rights?

No, investors can contact the Portnoy Law Firm at no cost for a case evaluation.

What allegations are made in the class action complaint?

The complaint alleges that Altimmune misrepresented drug efficacy and overstated prospects for partnerships.

Who should investors contact for more information?

Investors should contact Lesley Portnoy for discussing their legal rights and options.

Last updated: Jun 24, 2024